Gateway Biotechnology
Gateway Biotechnology is a clinical-stage biotech company focused on the development of novel drug and gene therapy treatments for hearing disorders, including tinnitus and noise-induced hearing loss. The company combines drug repurposing, new chemical entity discovery, and gene therapy for targeted solutions, leveraging extensive preclinical and clinical expertise. Gateway has received significant support through federal grants and contracts and has multiple preclinical and clinical programs in development.
Industries
N/A
Nr. of Employees
small (1-50)
Gateway Biotechnology is currently seeking investment
Gateway Biotechnology is seeking a series-a investment in the range of 5m-20m
Products
A repurposed formulation of an FDA-approved anticonvulsant targeting T-type calcium channels, developed for the prevention and treatment of acute noise-induced hearing loss. Underwent Phase 2 clinical evaluation with an incomplete trial due to pandemic-related enrollment issues.
A nasal formulation of an FDA-approved drug designed for targeted delivery to the brain and inner ear for recent-onset tinnitus relief, offering improved drug concentration and reduced systemic side effects.
A gene therapy platform using DREADD technology to modulate inhibitory neurons in the caudate nucleus for the suppression of severe, chronic tinnitus.
A newly synthesized chemical entity under animal pharmacodynamic and pharmacokinetic evaluation for potential efficacy in tinnitus treatment.
A repurposed formulation of an FDA-approved anticonvulsant targeting T-type calcium channels, developed for the prevention and treatment of acute noise-induced hearing loss. Underwent Phase 2 clinical evaluation with an incomplete trial due to pandemic-related enrollment issues.
A nasal formulation of an FDA-approved drug designed for targeted delivery to the brain and inner ear for recent-onset tinnitus relief, offering improved drug concentration and reduced systemic side effects.
A gene therapy platform using DREADD technology to modulate inhibitory neurons in the caudate nucleus for the suppression of severe, chronic tinnitus.
A newly synthesized chemical entity under animal pharmacodynamic and pharmacokinetic evaluation for potential efficacy in tinnitus treatment.
Expertise Areas
- Hearing loss drug development
- Tinnitus therapeutics
- Preclinical animal modeling
- Gene therapy for neuro-otology
Key Technologies
- Intranasal drug delivery
- Rodent behavioral modeling
- Auditory brainstem response analysis
- Gene therapy using chemogenetic tools
Key People
Co-Founder
Chief Medical Officer & Co-Founder
Co-Founder
Chief Medical Officer & Co-Founder
News & Updates
Secured intellectual property protection on novel approaches for hearing loss and tinnitus therapies.
Obtained extensive non-dilutive funding through federal grants and contracts to support research and development of therapies.
Contributed to scientific literature in the field of hearing disorders and auditory neuroscience.
An article discussing a calibration method to minimize variability in auditory evoked potentials.
Study highlights the need for protective treatments during certain surgical procedures due to risk of hearing loss in the unoperated ear.
Research presentation on the identification of functional biomarkers associated with age-related cochlear synaptopathy at the ARO 48th Annual MidWinter Meeting.
Secured intellectual property protection on novel approaches for hearing loss and tinnitus therapies.
Obtained extensive non-dilutive funding through federal grants and contracts to support research and development of therapies.
Contributed to scientific literature in the field of hearing disorders and auditory neuroscience.
An article discussing a calibration method to minimize variability in auditory evoked potentials.
Study highlights the need for protective treatments during certain surgical procedures due to risk of hearing loss in the unoperated ear.
Research presentation on the identification of functional biomarkers associated with age-related cochlear synaptopathy at the ARO 48th Annual MidWinter Meeting.